---
annotation-target: fmed-09-948210.pdf
---


>%%
>```annotation-json
>{"created":"2022-09-24T06:22:14.861Z","updated":"2022-09-24T06:22:14.861Z","document":{"title":"Donor-derived cytomegalovirus-cytotoxic T lymphocytes and leflunomide successfully control refractory cytomegalovirus infections and disease of multiple sites after allogeneic-hematopoietic stem cell transplantation: A case report","link":[{"href":"urn:x-pdf:1455ef1424e7f677bd06bd25c76a7fca"},{"href":"vault:/hematology-theroy/papers/yanxiaojing/fmed-09-948210.pdf"}],"documentFingerprint":"1455ef1424e7f677bd06bd25c76a7fca"},"uri":"vault:/hematology-theroy/papers/yanxiaojing/fmed-09-948210.pdf","target":[{"source":"vault:/hematology-theroy/papers/yanxiaojing/fmed-09-948210.pdf","selector":[{"type":"TextPositionSelector","start":1815,"end":2562},{"type":"TextQuoteSelector","exact":"Drug-resistant cytomegalovirus (CMV) infection after hematopoietic stem celltransplantation (HSCT) often leads to morbidity and mortality. Several studieshave shown that CMV-cytotoxic T lymphocytes (CTLs) can overcome drug-resistant CMV infection, but still many questions remain unanswered. Here, wepresent a case of refractory CMV infection after allogeneic HSCT (allo-HSCT).Donor-derived CMV-CTLs failed to eliminate the virus in unique peripheralblood on the first application, when 70 mg methylprednisolone (MP) wastaken per day. After a second attempt with a combination of 8 mg MPwith leflunomide, a complete and persisting clearance of all involved sites,including peripheral blood, urinary system, leptomeninges, and retina, wasachieved. ","prefix":"ersity, Shenyang,Liaoning, China","suffix":"To summarize, intravenous infusi"}]}]}
>```
>%%
>*%%PREFIX%%ersity, Shenyang,Liaoning, China%%HIGHLIGHT%% ==Drug-resistant cytomegalovirus (CMV) infection after hematopoietic stem celltransplantation (HSCT) often leads to morbidity and mortality. Several studieshave shown that CMV-cytotoxic T lymphocytes (CTLs) can overcome drug-resistant CMV infection, but still many questions remain unanswered. Here, wepresent a case of refractory CMV infection after allogeneic HSCT (allo-HSCT).Donor-derived CMV-CTLs failed to eliminate the virus in unique peripheralblood on the first application, when 70 mg methylprednisolone (MP) wastaken per day. After a second attempt with a combination of 8 mg MPwith leflunomide, a complete and persisting clearance of all involved sites,including peripheral blood, urinary system, leptomeninges, and retina, wasachieved.== %%POSTFIX%%To summarize, intravenous infusi*
>%%LINK%%[[#^l51cn59wpwk|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^l51cn59wpwk


>%%
>```annotation-json
>{"created":"2022-09-24T06:23:35.830Z","updated":"2022-09-24T06:23:35.830Z","document":{"title":"Donor-derived cytomegalovirus-cytotoxic T lymphocytes and leflunomide successfully control refractory cytomegalovirus infections and disease of multiple sites after allogeneic-hematopoietic stem cell transplantation: A case report","link":[{"href":"urn:x-pdf:1455ef1424e7f677bd06bd25c76a7fca"},{"href":"vault:/hematology-theroy/papers/yanxiaojing/fmed-09-948210.pdf"}],"documentFingerprint":"1455ef1424e7f677bd06bd25c76a7fca"},"uri":"vault:/hematology-theroy/papers/yanxiaojing/fmed-09-948210.pdf","target":[{"source":"vault:/hematology-theroy/papers/yanxiaojing/fmed-09-948210.pdf","selector":[{"type":"TextPositionSelector","start":2927,"end":4026},{"type":"TextQuoteSelector","exact":"Cytomegalovirus (CMV) reactivation after hematopoieticstem cell transplantation (HSCT) is a common complication(1). Subsequent therapy with a long-term exposure to anti-CMV drugs might lead to a refractory CMV infection anddisease (2). The cause of a refractory infection can be dueto either genetic or non-genetic mechanisms. Donor-derivedCMV-specific cytotoxic T lymphocytes (CMV-CTLs) facilitate acompletely different approach than traditional anti-CMV drugsand are thus a good choice for any mechanism of resistancewhile supporting a patient to quickly reacquire immunityagainst CMV, even under immunosuppressive conditions afterHSCT (3–5). As a high dose of corticosteroid often contributesto the failure of such therapy (6, 7), a question has arisen aboutwhat is the maximal level of corticosteroid, which might haveless to no effect on CMV-CTLs? Limited case reports disclosethat CMV-CTLs can penetrate blood–brain barrier (BBB) andblood vitreous barrier (8). More clinical studies are requiredto confirm the effects of CMV-CTLs on CMV infection in theretina and central nervous system (CNS).","prefix":"389/fmed.2022.948210Introduction","suffix":"In this study, we presented a ca"}]}]}
>```
>%%
>*%%PREFIX%%389/fmed.2022.948210Introduction%%HIGHLIGHT%% ==Cytomegalovirus (CMV) reactivation after hematopoieticstem cell transplantation (HSCT) is a common complication(1). Subsequent therapy with a long-term exposure to anti-CMV drugs might lead to a refractory CMV infection anddisease (2). The cause of a refractory infection can be dueto either genetic or non-genetic mechanisms. Donor-derivedCMV-specific cytotoxic T lymphocytes (CMV-CTLs) facilitate acompletely different approach than traditional anti-CMV drugsand are thus a good choice for any mechanism of resistancewhile supporting a patient to quickly reacquire immunityagainst CMV, even under immunosuppressive conditions afterHSCT (3–5). As a high dose of corticosteroid often contributesto the failure of such therapy (6, 7), a question has arisen aboutwhat is the maximal level of corticosteroid, which might haveless to no effect on CMV-CTLs? Limited case reports disclosethat CMV-CTLs can penetrate blood–brain barrier (BBB) andblood vitreous barrier (8). More clinical studies are requiredto confirm the effects of CMV-CTLs on CMV infection in theretina and central nervous system (CNS).== %%POSTFIX%%In this study, we presented a ca*
>%%LINK%%[[#^6p8zx9j7etm|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^6p8zx9j7etm


>%%
>```annotation-json
>{"created":"2022-09-24T06:42:48.453Z","updated":"2022-09-24T06:42:48.453Z","document":{"title":"Donor-derived cytomegalovirus-cytotoxic T lymphocytes and leflunomide successfully control refractory cytomegalovirus infections and disease of multiple sites after allogeneic-hematopoietic stem cell transplantation: A case report","link":[{"href":"urn:x-pdf:1455ef1424e7f677bd06bd25c76a7fca"},{"href":"vault:/hematology-theroy/papers/yanxiaojing/fmed-09-948210.pdf"}],"documentFingerprint":"1455ef1424e7f677bd06bd25c76a7fca"},"uri":"vault:/hematology-theroy/papers/yanxiaojing/fmed-09-948210.pdf","target":[{"source":"vault:/hematology-theroy/papers/yanxiaojing/fmed-09-948210.pdf","selector":[{"type":"TextPositionSelector","start":10380,"end":11230},{"type":"TextQuoteSelector","exact":" increase of more than onelog fold change of virus DNA copies in blood and a subsequentoccurrence of CMVR under long-term therapy with foscarnetboth indicated the resistance to the drug, even though noknown defined mutation on UL54 and UL97 was found inthe blood sample. Finally, additional resistant evidence showedthat ganciclovir and foscarnet failed to decrease the copiesof CMV in aqueous humor after weekly bilateral intraocularinjections. The difficult question remained to choose a therapyin order to effectively treat the patient. As it was not feasible torun sequencing on a sample of aqueous humor, we could notselect sensitive anti-CMV drugs, according to UL54 and UL97gene mutations. In addition, neither systemic administration ofganciclovir nor maribavir and letermovir could be applied, dueto a poor neutrophil level or unavailability","prefix":"D after allo-HSCT. Initially, an","suffix":".This is why we concluded CMV-CT"}]}]}
>```
>%%
>*%%PREFIX%%D after allo-HSCT. Initially, an%%HIGHLIGHT%% ==increase of more than onelog fold change of virus DNA copies in blood and a subsequentoccurrence of CMVR under long-term therapy with foscarnetboth indicated the resistance to the drug, even though noknown defined mutation on UL54 and UL97 was found inthe blood sample. Finally, additional resistant evidence showedthat ganciclovir and foscarnet failed to decrease the copiesof CMV in aqueous humor after weekly bilateral intraocularinjections. The difficult question remained to choose a therapyin order to effectively treat the patient. As it was not feasible torun sequencing on a sample of aqueous humor, we could notselect sensitive anti-CMV drugs, according to UL54 and UL97gene mutations. In addition, neither systemic administration ofganciclovir nor maribavir and letermovir could be applied, dueto a poor neutrophil level or unavailability== %%POSTFIX%%.This is why we concluded CMV-CT*
>%%LINK%%[[#^qy2wzzzl0jj|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^qy2wzzzl0jj
